Monthly Archives: January 2017

Free HIFU Info Session Scheduled for February

Do you have prostate cancer? There is now a non-invasive treatment option. Join Dr. Michael Lazar of California HIFU for a special Prostate Cancer Treatment Information session scheduled for Thurs., Feb. 16, 2017 at 7 p.m. This free session will be held at the Friedman Event Center, 4676 Mayette Ave., Santa Rosa, CA 95405. Dr. Lazar will discuss how Sonablate HIFU can treat Prostate Cancer with lower risk of side effects such as impotence and incontinence. HIFU is radiation free - provides quick recovery - requires no chemotherapy and no surgery. Free and open to the public. Call for reservations today Jennifer Radovich 707-546-5553. Refreshments will be provided. Brought to you by HIFU Prostate Services and California HIFU.

2017-12-13T13:37:21+00:00January 31st, 2017|

Prostate Cancer Rates Take a Nose Dive Per Latest Statistics

Dr. Michael Lazar of California HIFU, Urologist and Prostate Cancer expert reflects on the latest American Cancer Society statics The results from the American Cancer Society’s newest report on cancer rates is good news for everyone and particularly good news for prostate cancer patients: incidents of cancer is down as is the likelihood of prostate cancer patients dying from the diagnosis. According to the report the cancer death rate has dropped from its peak of 215.1 in 1991 to 161.2 in 2014 (per 100K population), the most recent year for which data was available to analyze. Overall the decline in cancer is linked with decreases in smoking and advances in early detection and treatment. The four major cancer drops are: lung (- 43% between 1990 [...]

2017-06-07T08:43:49+00:00January 23rd, 2017|

Researchers unravel genetic codes to determine why inherited prostate cancer is so deadly

Prostate cancer researchers have discovered a key piece in the genetic puzzle of why men born with a BRCA2 mutation may develop aggressive localized cancers that resist treatment and become lethal for up to 50 per cent of patients within five years. Canadian and Australian prostate cancer researchers have discovered a key piece in the genetic puzzle of why men born with a BRCA2 mutation may develop aggressive localized cancers that resist treatment and become lethal for up to 50 per cent of patients within five years. The findings, published online in Nature Communications, show that BRCA2-associated tumours are already pre-set to be aggressive, even before treatment. This is because the genes normally involved in regulating cell growth and division are abnormal in the BRCA2-associated [...]

2017-12-13T13:37:21+00:00January 10th, 2017|

New research reveals evidence linking inflammation to increased prostate cancer risk

Dr. Michael Lazar of California HIFU discusses the latest research on prostate cancer which offers hope for future treatments and may help to prevent the disease from becoming aggressive. An interesting new study, conducted by Dr. Andrew Goldstein, an assistant professor of molecular biology and a team of UCLA researchers, highlights a previously unrecognized type of cell that is found in uncommonly high numbers in inflamed areas of the prostate gland. These cells are now thought to initiate prostate cancer in response to genetic mutations. The study results suggest inflammation increases overall risk for the disease by increasing the available number of affected cells that can develop into prostate cancer. “The findings from research such as this will hopefully lead to the development of better [...]

2017-12-13T13:37:21+00:00January 3rd, 2017|